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Emollient enhancement of the skin barrier from birth offers
effective atopic dermatitis prevention
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Yiyi Chen, PhD,f and Hywel C.Williams, DSc, FMedScib Portland, Ore, and Nottingham, Sheffield, and Dundee, United KingdomBackground: Atopic dermatitis (atopic eczema) is a chronic
inflammatory skin disease that has reached epidemic
proportions in children worldwide and is increasing in
prevalence. Because of the significant socioeconomic effect of
atopic dermatitis and its effect on the quality of life of children
and families, there have been decades of research focused on
disease prevention, with limited success. Recent advances in
cutaneous biology suggest skin barrier defects might be key
initiators of atopic dermatitis and possibly allergic sensitization.
Objective: Our objective was to test whether skin barrier
enhancement from birth represents a feasible strategy for
reducing the incidence of atopic dermatitis in high-risk neonates.
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818to apply full-body emollient therapy at least once per day starting
within 3 weeks of birth. Parents in the control arm were asked to
use no emollients. The primary feasibility outcome was the
percentage of families willing to be randomized. The primary
clinical outcome was the cumulative incidence of atopic
dermatitis at 6 months, as assessed by a trained investigator.
Results: Forty-two percent of eligible families agreed to be
randomized into the trial. All participating families in the
intervention arm found the intervention acceptable.
A statistically significant protective effect was found with the use
of daily emollient on the cumulative incidence of atopic dermatitis
with a relative risk reduction of 50% (relative risk, 0.50; 95%CI,
0.28-0.9; P 5 .017). There were no emollient-related adverse
events and no differences in adverse events between groups.
Conclusion: The results of this trial demonstrate that emollient
therapy from birth represents a feasible, safe, and effective
approach for atopic dermatitis prevention. If confirmed in
larger trials, emollient therapy from birth would be a simple
and low-cost intervention that could reduce the global burden of
allergic diseases. (J Allergy Clin Immunol 2014;134:818-23.)
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Atopic dermatitis (atopic eczema) is a chronic inflammatory skin
disease thathas reached epidemic proportions inchildrenworldwide
and is increasing in prevalence.1,2 Children with atopic dermatitis
experience intractable itch along with inflamed, cracked, and often
infected skin lesions. The onset of atopic dermatitis in childhood
often heralds the development of subsequent allergic disorders,
such as food allergy, asthma, and allergic rhinitis (the atopicmarch),
as well as neurodevelopmental disorders.3,4 Development of an
effective prevention strategy for atopic dermatitis and associated
allergic diseasewould represent amajor public health breakthrough.
Atopic dermatitis has been historically classified as an allergic
disease, given its association with IgE-mediated diseases, such as
food allergy. Prevention trials to date have primarily focused on
allergen avoidance. Unfortunately, the results of these studies
have been largely disappointing or inconsistent, and no single
accepted prevention strategy has emerged.5
Recent advances in cutaneous biology suggest epidermal
defects might be a key initiator of atopic dermatitis and possibly
allergic sensitization.6-8 Skin barrier dysfunction is now recog-
nized as central to the initiation and progression of atopic derma-
titis. These newfindings create an opportunity for the development
of novel prevention strategies focusing on the skin barrier. We hy-
pothesize that enhancement of a defective skin barrier early in life
might prevent or delay the onset of atopic dermatitis.
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enhancement because they provide the skin with a source of
exogenous lipids, improving its barrier properties.9-11 The results
of a previous case-control study and open-label trial suggest the
use of bland emollients from birth might protect against the onset
of skin inflammation in neonates.12,13 The objective for this study
was to test the hypothesis that emollient therapy from birth repre-
sents a safe, feasible, and efficacious approach to the prevention
of atopic dermatitis (Fig 1).
METHODS
Study design
This was amulticenter, multinational, 2-arm parallel-group, assessor-blind,
randomized (1:1) controlled pilot trial of 6 months’ duration. The intervention
started within 3 weeks of birth.
Participants
Infants at high risk of eczema, which was defined as having a parent or full
sibling who has (or had) physician-diagnosed atopic dermatitis, asthma, or
allergic rhinitis, were included. The strongest and most established risk factor
for atopic dermatitis is a family history of atopic disease.14,15 Thus to qualify
for this study, neonates had to have had 1 first-degree relative with a history of
allergic rhinitis, asthma, or atopic dermatitis. Between 25% and 40% of chil-
dren with a family history of atopic disease have atopic dermatitis in the first
year of life, with some reports putting the risk at greater than 60%.16 Infants
needed to be in overall good health, and the mother needed to be at least 16
years of age at delivery and capable of providing informed consent. If mothers
had taken Lactobacillus rhamnosus supplements during pregnancy, their in-
fants were excluded. Infants were excluded if they were born before 37 weeks’
gestation or if they had a major congenital anomaly, hydrops fetalis, an immu-
nodeficiency syndrome, a severe genetic skin disorder, or a serious skin con-
dition that would make the use of emollients inadvisable.
Intervention
Parents in the intervention group were offered a choice of 3 emollients of
different viscosities (an oil, a cream/gel, or an ointment) that had been selected
based on previous data regarding their safety, tolerability, or barrier-protective
qualities.17-22 In the United Kingdom emollient choices were sunflower seed oil
(William Hodgson and Co, Congleton, United Kingdom), Doublebase Gel
(Dermal Laboratories, Hitchin, United Kingdom), and liquid paraffin 50% in
white soft paraffin. In the United States parents were offered the same sunflower
seed oil as used in theUnitedKingdom,CetaphilCream(GaldermaLaboratories,
Fort Worth, Tex), or Aquaphor Healing Ointment (Beiersdorf, Chester, Ohio).
We used sunflower seed oil with a high ratio of linoleic/oleic acid to optimize
the positive skin barrier effects.23 None of the emollients offered contain sodium
lauryl sulfate because this emulsifier has been shown to adversely affect the skin
barrier.24 Parents were asked to apply the emollient to the baby’s entire body sur-
face,with the exceptionof the scalp, starting as soon as possibleafterbirth (within
a maximum of 3 weeks) and continuing until the infant was 6 months of age.
Both the intervention and control groups were given an infant skin care
advice booklet, which reflected current guidelines.25 Parents are advised (1) to
avoid soap and bubble bath; (2) use amild, fragrance-free synthetic cleanser de-
signed specifically for babies; (3) avoid bath oils and additives; (4) use a mild,
fragrance-free shampoo designed specifically for babies and avoid washing the
suds over the baby’s body; and (5) avoid using baby wipes, where possible.
Outcomes
The primary purpose of this trial was to determine the feasibility of this
approach for atopic dermatitis prevention in preparation for larger trials. Thus
the primary outcome for this pilot study was the proportion of eligible families
who were willing to be randomized.
Secondary outcomes were as follows:
d proportion of families eligible for the trial;
d proportion of families accepting the initial invitation to participate;d percentage of early withdrawals;
d proportion of families who found the intervention acceptable;
d reported adherence with intervention;
d amount of contamination in the control group;
d age of onset of eczema and proportion of transient cases;
d incidence of emollient-related adverse events;
d success of blinding of the assessor to allocation status; and
d cumulative incidence of eczema at 6 months, as determined by an
investigator.
Filaggrin mutation testing was performed in the McLean laboratory
(Dundee, United Kingdom), evaluating the 4 loss-of-function mutations
(R501X, 2282del4, S3247X, and R2447X) that are most prevalent in
populations of white European ancestry by using TaqMan allelic discrimina-
tion (Thermo Fisher Scientific, Waltham, Mass), as described previously.26Recruitment and setting
Recruitment took place in the United Kingdom and the United States
between May 2010 and May 2011. In the United Kingdom research nurses
were based in 3 acute National Health Service hospital trusts (Nottingham
University Hospitals, Derby Hospitals, and United Lincolnshire Hospitals)
and 1 general practice surgery (the Surgery@Wheatbridge, Chesterfield). In
the United States the study recruited in 1 hospital, Oregon Health & Science
University Hospital and Clinics (Portland, Oregon).Visit schedule and randomization
Participation in the trial was for 6 months’ duration. Methods of identifying
suitable families differed between the United Kingdom and the United States.
In the United Kingdom families were usually identified and screened during
pregnancy by means of advertisement. After the family had made contact with
the study team and initial eligibility checks had been carried out by the
coordinating center, the research nurse carried out the screening and consent
visit, usually at the family home. The baseline visit, including randomization,
then took place within 3 weeks of delivery, usually as a home visit. In the
United States families were identified by study coordinators visiting the
postnatal wards each day and approaching parents about the study directly.
After giving parents time to consider the study, the study coordinators returned
to the family to obtain written consent and randomize the subjects.
Infants were randomized at a 1:1 ratio using random block sizes to either
the intervention or control group with a central, Web-based, computer-
generated, Internet randomization service provided by the Nottingham
Clinical Trials Unit. The allocation list was held by the Nottingham Clinical
Trials Unit and concealed from trial investigators and other trial staff.
Allocation was only released to the research nurse by telephone once eligible
participants’ details were irrevocably entered into the online database by the
coordinating center staff. Randomization was stratified by the recruiting
research nurse. In the case of multiple births, the firstborn was the index child.
The research nurse contacted parents by telephone at 10 days and 6 weeks,
with a face-to-face visit at 12 weeks (usually at home in the United Kingdom
and as a clinic visit in the United States). This was then followed by a further
telephone call at 18 weeks, and the final contact was a clinic visit at 24 weeks
for an assessment by the dermatologist or dermatology specialist nurse, who
conducted a blinded assessment of the skin. In addition to these scheduled
contact points, parents were encouraged to contact the research nurse if they
had any concerns about the child’s skin. If parents reported symptoms of
eczema, then an unscheduled visit to the hospital to see the dermatologist was
arranged so that the presence of eczema could be confirmed.Blinding
It was not possible to blind parents in a trial of daily emollient application.
An independent outcome assessor who was blinded to treatment allocation
performed the skin examinations and diagnosis of eczema. This was usually a
general practitioner, dermatologist, or dermatology nurse specialist. The
statistician was blinded to treatment group until the analysis was complete.
FIG 1. Skin barrier protection might prevent atopic dermatitis development. FLG, Filaggrin.
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The study was given ethical approval by the Nottingham Research Ethics
Committee 1 in the United Kingdom (reference 09/H0407/43) and the Oregon
Health & Science University Institutional Review Board in the United States
and approved by all participating institutions. The trial was registered at
Current Controlled Trials (ISRCTN84854178).Sample size
This was a pilot study and therefore not powered to establish the
effectiveness of the intervention. The sample size was dictated by the time
and resources available and was based on the primary outcome of willingness
to randomize. Use of 100 families was calculated to provide an estimatewithin
10 percentage points for a 95% CI of the proportion willing to be randomized,
assuming between 40% and 60% were willing to be randomized.Data analysis
The main clinical end point was the week 24 cumulative incidence of
physician-diagnosed eczema. Infants were classified as having eczema if
either the investigator or another medically qualified person (eg, a general
practitioner) judged that the infant had eczema on examination at any point
during the 24-week intervention period. The primary clinical end point
analysis was conducted on an intent-to-treat basis using a complete case
approach. Multiple sensitivity analyses were performed for the primary
clinical end point.Missing datawere imputed for infants withmissingweek 24
skin examination data because they were either lost to follow-up or withdrew
during the 24-week intervention period (for reasons other than developed
eczema). The following imputations were performed.
Multiple imputation. SAS procedure PROC MI was used to
impute the missing data by using the Markov Chain Monte Carlo method,
assuming the data are missing at random. By using variables from a logistic
regression model, multiple imputation was performed to replace each missing
values with 4 imputed values. SAS procedure PROCMIANALYSIS was used
to combine the results from 5 imputed data sets for final inference results.
Baseline variables used for the multiple imputation model were as follows:
intervention group, study center, paternal asthma, maternal asthma, and
paternal eczema. This combination of variables was found to best predict the
outcome of eczema by using logistic regression with the smallest Akaike
information criterion.Imputated data sets. Eczema imputation was defined as all those
withmissing data assumed to have eczema.No eczema imputationwas defined
as all those with missing data assumed to not have eczema.Worst-case impu-
tationwas defined as all those with missing data in the emollient arm assumed
to have eczema and all those in the control arm assumed to not have eczema
(worst case). Best-case imputation was defined as all those with missing data
in the control arm assumed to have eczema and all those in the emollient arm
assumed to not have eczema (best case).RESULTS
Feasibility end points
A total of 430 families were identified, of which 135 (31%)
were not eligible. Of the 295 eligible families, 124 (42%)
accepted the initial invitation to participate and were randomized
(see the CONSORT flow diagram, Fig 2). The planned sample
size was exceeded to allow all sites to enroll an adequate sample.
Baseline characteristics were similar between treatment groups
(Table I). The number of babies with a loss-of-function mutation
in the skin barrier gene filaggrin, the strongest known genetic pre-
dictor of atopic dermatitis,27 was also similar between the 2
groups. By 6 months, 9 participants in the intervention arm and
7 in the control arm were lost to follow-up or withdrew in the
intervention arm (12.9% attrition). All parents reported they
found the emollient ‘‘acceptable,’’ and none of the families with-
drew because of the emollient.
In the intervention group the cream/gel formulation was the
preferred emollient (67.2%), followed by oil (23.4%) and then
ointment (9.4%). Approximately 85% of parents in the interven-
tion group reported using emollients at least 5 days per week in
the intervention group at 6 months (Table II). Eight (13.3%) par-
ents in the control group reported using emollients in a way that
mirrored the intervention (ie, regular generalized application of
emollient for reasons other than the treatment of cradle cap, nappy
rash, or eczema). These participants remained as control subjects
in the analyses based on the intent-to-treat principle. The blinding
was not maintained for 5 (4%) of 124 skin examinations, and this
FIG 2. CONSORT flow diagram.
TABLE I. Baseline characteristics
Characteristic
Total
no.
Control, no. (%),
n 5 60
Emollient, no. (%),
n 5 64
Mother with eczema 124 27 (45.0) 23 (35.9)
Mother with asthma 124 23 (38.3) 18 (28.1)
Father with eczema 124 13 (21.7) 16 (25.0)
Father with asthma 124 10 (16.7) 14 (21.9)
At least 1 parent with
eczema
124 30 (50.0) 33 (51.6)
Both parents with eczema 124 5 (8.3) 3 (4.7)
Cesarean delivery 124 17 (28.3) 16 (25.0)
Any FLG mutation 95 8 (17.8) 13 (26.0)
FLG heterozygous 95 6 (13.3) 13 (26.0)
FLG homozygous/compound
heterozygous
95 2 (4.4) 0 (0.0)
FLG, Filaggrin.
TABLE II. Emollient group adherence
Emollient use Week 6* Week 12 Week 18* Week 24
None 0 0 1 (1.8%) 0
1-2 d/wk 1 (1.9%) 0 1 (1.8%) 3 (5.6%)
3-4 d/wk 4 (7.4%) 5 (9.1%) 5 (8.8%) 5 (9.3%)
5-6 d/wk 7 (13.0%) 8 (14.6%) 7 (12.3%) 2 (3.7%)
Everyday 42 (77.8%) 42 (76.4%) 43 (75.4%) 44 (81.5%)
Total 54 55 57 54
*Telephone visit.
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assessor.Clinical end points
Daily emollient use significantly reduced the cumulative
incidence of atopic dermatitis at 6 months (43% in the control
group vs 22% in the emollient group). This corresponds to a
relative risk reduction of 50% (relative risk, 0.50; 95% CI, 0.28-
0.90;P5 .017). A sensitivity analysis using amultiple imputation
approach for missing data from the 16 participants who withdrew
or were lost to follow-up showed a similar statistically significant
protective effect of emollient therapy as the complete case results
(data not shown). Further sensitivity analyses were performed by
imputing missing data, assuming those with missing data either
all had eczema or all did not have eczema, and found similarsignificant results in 3 of the 4 scenarios (Table III). We were un-
able to assess the age of onset of eczema (and thus assess whether
cases were transient) with any precision because of the low
numbers of subjects who presented with eczema symptoms
before the 6-month visit (data not shown). Three superficial cuta-
neous infections occurred in each group, all of whichwere consid-
ered mild in nature. There were no reports of irritant or allergic
contact dermatitis.DISCUSSION
This study provides the first randomized controlled trial
evidence that daily full-body emollient therapy from birth can
prevent atopic dermatitis. In our study, parents adhered
adequately to the simple intervention, and no significant adverse
events occurred. The morbidity of atopic dermatitis and the
increasing prevalence and potential toxicity of current immuno-
suppressant therapies make disease prevention an important goal.
Atopic dermatitis prevention was listed as an ‘‘urgent call for
research’’ in the United KingdomHealth Technology Assessment
Systematic Review of Atopic Dermatitis Therapy published more
than decade ago.28 However, despite the publication of more than
TABLE III. Additional sensitivity analyses
Case Total no. Had AD (control group) Had AD (emollient group) RR (95% CI) P value
Complete (no imputation) 108 23/53 (43.4%) 12/55 (21.8%) 0.50 (0.28-0.90) .017
Missing (assumed to develop AD) 124 30/60 (50.0%) 21/64 (32.8%) 0.66 (0.43-1.01) .03
Missing (assumed not to develop AD) 124 23/60 (38.3%) 12/64 (18.8%) 0.49 (0.27-0.89) .02
Worst-case scenario* 124 23/60 (38.3%) 21/64 (32.8%) 1.0 (0.61-1.62) .99
Best-case scenario 124 30/60 (50.0%) 12/64 (18.8%) 0.38 (0.2-0.66) <.001
AD, Atopic dermatitis; RR, relative risk.
*Missing in emollient group assumed to have AD and in control group assumed not to have AD.
Missing in emollient group assumed not to have AD and in control group assumed to have AD.
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titis, themajority of which have evaluated allergen avoidance pre-
ventive strategies, no strategy has been generally accepted as
effective.5
Although not previously studied for primary prevention,
emollient therapy plays an integral role in the management of
established atopic dermatitis.29 The exact mechanisms through
which emollients exert their positive effects are not completely
understood. We propose that emollients correct subclinical skin
barrier dysfunction and early inflammation in predisposed infants
before atopic dermatitis development by improving skin hydra-
tion and reducing skin permeability. This skin barrier enhance-
ment prevents skin dryness and cracking, as well as inhibiting
irritant and allergen penetration into the epidermis, which are po-
tential initiators of skin inflammation.
Future studies should address the potential for skin barrier
protection to reduce IgE sensitization. Both human and mouse
studies suggest that the skin barrier might be a site for IgE
sensitization.30-32 If so, this approachmight also represent a novel
allergic asthma and food allergy prevention strategy. More data
regarding the optimum emollients for atopic dermatitis preven-
tion are also needed. Emollients should improve skin barrier func-
tion, be free of irritants and potential allergens, and be low cost
and easy to use so that the intervention can be used worldwide.
It is unclear whether formulations that contain special additives,
such as ceramides, improve the skin barrier or provide better clin-
ical outcomes than simple petrolatum-based emollients.
The strengths of our study include the randomized controlled
trial design, blinded outcome assessment, and potential external
validity of studying the intervention in 2 countries and several
centers. The major limitation of this study was the short follow-up
time and small number of participants. Because it is possible that
the use of emollients in our pilot study simply masked very mild
eczema by exerting a weak anti-inflammatory effect, long-term
follow-up beyond the intervention is crucial for any future
randomized trials, and such a study is underway in the United
Kingdom.
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Clinical implications: Emollient therapy from birth represents
a novel approach to atopic dermatitis primary prevention. We
anticipate these data will encourage larger trials of this
approach in various populations.REFERENCES
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